Domainex's Drug Discovery Pipeline

Domainex specializes in drug discovery and has an excellent pedigree, delivering an average of one candidate every year for the past six years on behalf of its collaborators and clients. Domainex has also utilized its expertise and proprietary technologies to develop its own internal pipeline - focussed on exciting and novel, but challenging drug targets.

Domainex's lead programme targets key kinases (TBK1/IKKe) involved in innate immunity, to develop new disease-modifying drugs against inflammatory indications such as COPD and psoriasis. Domainex's compounds have been demonstrated to be efficacious in in vivo models and we are now quickly progressing to GLP studies.

Domainex has also focussed its capabilities on the development of an epigenetics-targeted pipeline, namely against the protein methyl-transferases (PKMT). Domainex is a leader in PKMT drug discovery and is developing highly potent, selective and drug-like compounds.

Target Indication Target expression Assay Crystal Structure Hit ID H2L Lead Optimisation Candidate Nomination
TBK1/IKKε Inflammatory Disease (COPD + psoriasis) Tick Tick Tick Tick Tick Tick 2015
G9a Oncology Tick Tick Tick Tick Tick Tick  
SMYD3 Oncology Tick Tick   Tick Tick Tick  
EZH2   Tick Tick   Tick      
KMT target 4 Oncology Tick Tick   Tick      
KMT target 5 Oncology Tick Tick Tick        


2nd November to 4th November 2015
Munich, Germany


11th May 2015
11th May 2015 Domainex Ltd. (Cambridge, UK) today announced that The US and European Patent Offices have now granted Domainex patents US 8,962,609...
9th July 2014
Domainex Ltd, a UK-based drug discovery company developing first-in-class small-molecule inhibitors of two closely-related pro-inflammatory kinases...


Domainex aims to progress its programmes to IND-enabling studies, but to seek a partner or investment to take further forward. Currently its TBK1/IKKe programme is available for outlicensing and we are happy to discuss strategic collaborations regarding our epigenetics work. Contact us for more information.